According to the New Zealand Vaping Advocacy Community (AVCA), claims by the Asthma and Respiratory Foundation of New Zealand (ARFNZ) that e-cigarettes cause lung damage are unfounded. As part of World Chronic Obstructive Pulmonary Disease (COPD) Day on November 16th, ARFNZ urged New Zealanders to steer clear of e-cigarettes to protect their lung health and avoid COPD.
The Asthma and Respiratory Foundation of New Zealand has once again made a health claim without providing any evidence to support it. If they want their warning to be taken seriously, they need to provide some evidence," said Nancy Loucas, co-founder of AVCA.
The AVCA recommends that ARFNZ refer to the medical research published by Professor Riccardo Polosa in international journals. The professor is a renowned expert in the field of respiratory health and tobacco harm reduction (THR), having received numerous awards.
Professor Polosa's work provides comprehensive evidence that patients suffering from severe chronic obstructive pulmonary disease experience improved respiratory symptoms after completely switching from cigarettes to e-cigarettes. Another review conducted by Professor Polosa concluded that e-cigarettes are far less damaging to the lungs compared to smoking.
Electronic cigarettes are not perfect, but their harm is far less than smoking. ARFNZ did not support the Ministry of Health in using electronic cigarettes as an effective smoking cessation tool, but instead continued to be unreasonable. If ARFNZ hopes to achieve a smoke-free New Zealand by 2025, it needs to recognize the role of electronic cigarettes instead of scaring those who are eager to quit smoking," said Ms. Loucas.
She stated that New Zealand has implemented an effective tobacco harm reduction (THR) strategy, leading to the country's overall smoking rate being at its lowest historical level. With the government renewing its focus on the Aotearoa 2025 Smokefree plan - aiming to reduce smoking by 5% - smoke-free is now becoming a reality.
ARFNZ is making every effort to prevent the remaining smokers from switching to safer alternatives. They fail to mention that no New Zealanders have died from using e-cigarettes, and also fail to mention that the UK Public Health Department still strongly believes that e-cigarettes are 95% less harmful than smoking combustible cigarettes.
Ms. Loucas suggests that individuals using or associated with electronic cigarettes seeking trustworthy advice should visit the Ministry of Health's website, www.vapingfacts.health.nz/.
The amendment for smoke-free environments and regulated products (tobacco smoking) will be returned from the Health Committee report by December 1st.
According to the AVCA, ARFNZ is making maximum efforts to revive the comprehensive e-cigarette legislation that was due in the country in 2020. In the meantime, around 5,000 New Zealanders die every year from smoking-related diseases.
The parliament is passing a bill that will address the harmful effects of cigarettes by restricting their use and appeal. This should be the focus of ARFNZ. However, instead, they continue to undermine the government and health department's stance on the e-cigarette issue, causing confusion among consumers," she said.
The AVCA has stated that ARFNZ is not the only entity engaging in the dissemination of erroneous information. The World Health Organization (WHO) continues to claim that there is mounting evidence that e-cigarettes cause harm to the lungs. However, a recent white paper authored by international THR experts concluded that such claims are "shameful and outright lies.
Ms. Loucas presented a white paper at the 5th Asia Harm Reduction Forum (AHRF 2022) titled "Disrupting Public Health: A Consumer Perspective.
ARFNZ should join the country's ten-year smoke-free initiative and successful THR strategy. If it cannot accept the many positive case studies of science and non-smokers, it should at least remain silent," said Nancy Loucas.
Statement:
This article is compiled from third-party information and is intended for industry exchange and learning.
This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is only intended for industry communication and research purposes.
Due to limitations in the compiling proficiency, the translated article may not fully convey the same meaning as the original. Please refer to the original article for accuracy.
2FIRSTS aligns completely with the Chinese government on any domestic issues, as well as those involving Hong Kong, Macau, Taiwan, and foreign affairs.
The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for removal.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
